Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria (main):~* Untreated SCCHN of oral cavity (anterior tongue, floor of mouth, cheek)/soft palate, categories T1N1-2M0,T2N1-2M0,T3N0-2M0,T4N0-2M0 (T4 allowed only if invasion of mandible is negligible i. e. 5mm or less) scheduled for SOC~* Primary tumor and any positive node(s) measurable in 2 dimensions~* Normal immune function~* No immunosuppressives with 1 year of entry~* KPS\>70/100~* Age\>18~* Male or Female (non-pregnant)~* Life expectancy \>6 months~* Able to take oral medication~* Able to provide informed consent~Exclusion Criteria (main):~* Subjects to be treated with other than SOC~* Tumor invasion of bone (also see inclusion criteria)~* Tumor classifications T1N0, T2N0, T4N3, any TN classification with M1~* Tumors in locations other than those specified in inclusion criteria~* Active peptic ulcer (or on full-dose therapeutic anti-coagulants)~* Prior resection of jugular nodes ipsilateral to tumor~* Acute or chronic viral, bacterial immune or other disease associated with abnormal immune function~* Subjects on hemodialysis or peritoneal dialysis; or having a history of~* History of asthma, allergy to fluoroquinolone antibiotics, congestive heart failure, or on hemodialysis or peritoneal dialysis~* Any condition that in the opinion of the investigator would cause the subject to be unable to participate or tolerate the protocol regimen~* Failure to meet inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LI + CIZ + SOC (Type: EXPERIMENTAL): LI plus CIZ (cyclophosphamide, indomethacin and zinc-multivitamins) was given as neoadjuvant therapy prior to standard of care (SOC).
- Standard of Care (SOC) only (Type: ACTIVE_COMPARATOR): SOC for previously untreated SCCHN patients is currently surgery (with curative intent) followed by either radiotherapy or combined radiochemotherapy depending on the patient's risk status for recurrence as determined at surgery.
- LI + SOC (Type: EXPERIMENTAL): LI was administered without CIZ to determine the contribution of CIZ to the effects of LI.

Based on this trial design, predict the completion outcome and termination type (if applicable).